COG1410 is an apolipoprotein E-derived peptide. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease[1][2].
COG1410 (1-25 μM; 48 h) decreases the production and release of NO and TNFα in BV2 microglia cells[1].
COG1410 (0.3-0.6 mg/kg; a single i.v.) exhibits significant improvement on a short term test of vestibulomotor function and on a long term test of spatial learning and memory in mice[1].COG1410 (0.8 mg/kg; a single i.v.) improves vestibulomotor function, decreases poststroke locomotor asymmetry, and decreases infarct volume of the ipsilateral hemisphere in rats[2].
[1]. Laskowitz DT, et, al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma. 2007 Jul;24(7):1093-107.
[2]. Tukhovskaya EA, et, al. COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. J Neurosci Res. 2009 Feb 15;87(3):677-82.
[3]. Kuai L, et, al. Apolipoprotein E-Mimetic Peptide COG1410 Enhances Retinal Ganglion Cell Survival by Attenuating Inflammation and Apoptosis Following TONI. Front Neurosci. 2019 Sep 13;13:980.